These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8388827)

  • 21. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.
    Macadam AJ; Pollard SR; Ferguson G; Skuce R; Wood D; Almond JW; Minor PD
    Virology; 1993 Jan; 192(1):18-26. PubMed ID: 8390752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WHO recommendation on potential use of new poliomyelitis vaccines.
    Ghendon Y
    Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
    J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the attenuation of the Sabin type 3 oral polio vaccine.
    Almond JW; Westrop GD; Evans DM; Dunn G; Minor PD; Magrath D; Schild GC
    J Virol Methods; 1987 Aug; 17(1-2):183-9. PubMed ID: 2822753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses.
    Otelea D; Guillot S; Furione M; Combiescu AA; Balanant J; Candrea A; Crainic R
    Dev Biol Stand; 1993; 78():33-8. PubMed ID: 8099049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methods to Monitor Molecular Consistency of Oral Polio Vaccine.
    Chumakov KM
    Methods Mol Biol; 2016; 1387():263-77. PubMed ID: 26983740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant.
    Dedepsidis E; Pliaka V; Kyriakopoulou Z; Brakoulias C; Levidiotou-Stefanou S; Pratti A; Mamuris Z; Markoulatos P
    FEMS Immunol Med Microbiol; 2008 Apr; 52(3):343-51. PubMed ID: 18328076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania.
    Combiescu M; Guillot S; Persu A; Baicus A; Pitigoi D; Balanant J; Oprisan G; Crainic R; Delpeyroux F; Aubert-Combiescu A
    Arch Virol; 2007; 152(4):727-38. PubMed ID: 17195957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
    Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
    J Virol; 1988 Aug; 62(8):2828-35. PubMed ID: 2839704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil.
    Friedrich F; Da-Silva EF; Schatzmayr HG
    Acta Virol; 1996 Feb; 40(1):27-33. PubMed ID: 8886095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys.
    Lu Z; Asher DM; Levenbook IS; Chumakov KM
    Virology; 1996 Jun; 220(2):285-9. PubMed ID: 8661379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child.
    Adu F; Iber J; Bukbuk D; Gumede N; Yang SJ; Jorba J; Campagnoli R; Sule WF; Yang CF; Burns C; Pallansch M; Harry T; Kew O
    Virus Res; 2007 Jul; 127(1):17-25. PubMed ID: 17449127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(38):996-1001. PubMed ID: 17898693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans.
    Friedrich F
    Acta Virol; 1998 Jun; 42(3):187-94. PubMed ID: 9842449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
    Cáceres VM; Sutter RW
    Clin Infect Dis; 2001 Aug; 33(4):531-41. PubMed ID: 11462191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
    Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
    Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.